LISI GROUP - Integrated report 2020

LISI — 2020 INTEGRATED REPORT 75 What lessons do you learn from this crisis? During the lockdown phases, we recorded a record number of calls for tenders and requests for quotation from our customers, who took advantage of this period to review their cost base. Our position as preferred supplier in the markets where we operate explains why we are very much in demand. We have also harnessed these requests to put ourselves in a position to gain market share in certain segments where we wish to consolidate our positions. Potentially, the total volume of quotes issued during the health crisis could have a major effect on our sales revenue in the coming years. What is your outlook? We are now able to manage the rebound in the sector. We continued to invest in both productivity and capacity, in particular at the Hérouville, Neyron and Minneapolis sites. Demand should gradually pick up and we are in a position to be able to meet it, while maintaining our strategic choices in terms of developing new products for our customers. The crisis demonstrated the financial strength of the division, which proved to the market that it could continue to invest while protecting its cash flow. We are nowable tomanage the rebound in the sector. We continued to invest inbothproductivity and capacity, in particular at theHérouville, Neyron and Minneapolis sites. Strengthening of the US sales team LISI MEDICAL is positioned as a strategic supplier to the largest global players in the orthopedics markets, which occupy key positions on the US market. To strengthen its positions in this geographical area, LISI MEDICAL has undertaken the reorganization of its teams, hiring five dedicated sales representatives. This team, in charge of monitoring the field of business with the major OEMs in the American market, has been operational since September 2020. These recruitments demonstrate LISI MEDICAL’s ability to attract new talents in a very competitive market.